Compare AG & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AG | BEAM |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 2.6B |
| IPO Year | 2004 | 2019 |
| Metric | AG | BEAM |
|---|---|---|
| Price | $19.56 | $24.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $21.92 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 7.8M | 1.7M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $24.41 | N/A |
| Revenue Next Year | $10.68 | $33.77 |
| P/E Ratio | $143.01 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $10.19 | $20.23 |
| 52 Week High | $32.00 | $38.26 |
| Indicator | AG | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 40.17 |
| Support Level | $18.43 | $21.63 |
| Resistance Level | $20.00 | $28.87 |
| Average True Range (ATR) | 0.77 | 1.28 |
| MACD | -0.30 | -0.39 |
| Stochastic Oscillator | 34.50 | 25.71 |
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.